The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Advice for applying the Clonal Hematopoiesis Risk Score in clinical practice
In this video, Lachelle Weeks, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the Clonal Hematopoiesis Risk Score (CHRS) and its application in clinical practice, noting that while the score provides a population-level estimate of risk of progression to certain myeloid malignancies, there is a need for practicing hematologists to consider additional clinical context on a patient-by-patient basis. Dr Weeks highlights that certain clinical features, including sickle cell disease (SCD), chemotherapy, or radiation therapy, can accelerate risk beyond what is estimated by the CHRS. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
